 "Cipla, Cipla logo, Cipla headquarters")
Drug firm Cipla has witnessed three senior-level exits, including that of the company's Executive Vice-President and CEO for India business Nikhil Chopra.
The other two executives are Nikhil Lalwani, head of India prescription business, and Kunal Khanna, cluster head of chronic and emerging business development and portfolio.
"They have served significant tenures in Cipla; we deeply value their contribution, respect their professional aspirations and wish them all the best," Cipla said in a statement.
The company's rich legacy of care and strong sense of purpose rooted in a culture of meritocracy and high performance standards have made Cipla an employer
